Haemonetics earnings release, May 7, 2026
Haemonetics Reports Fourth Quarter and Fiscal 2026 Results;
Provides Fiscal 2027 Guidance
Boston, MA, May 7, 2026
- Haemonetics Corporation (NYSE: HAE) reported financial results for its fourth quarter and fiscal 2026, which ended March 28, 2026:
__________
(1)
Excludes the impacts of currency fluctuation, the divestiture of the Whole Blood product line as of its completion in January 2025 and the exit of certain liquid solution products. The Company's acquisition of Vivasure Medical Limited ("Vivasure") in January 2026 had no impact on organic revenue growth rates and is not separately quantified.
(2)
In addition to the adjustments for organic revenue, further excludes the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.
Chris Simon, Haemonetics’ CEO, stated: "Strong fourth quarter performance was largely driven by our core platforms, with outperformance in Plasma and Blood Management Technologies, and sequential improvement in Interventional Technologies. We successfully completed our four-year long-range plan, having built a more diversified, sustainable, and durable business and delivering impressive results against ambitious multi-year goals. With a strengthened competitive position and focus on disciplined execution, we have momentum for fiscal 2027 and beyond."
GAAP RESULTS
Fourth quarter fiscal 2026 revenue was
$346.4 million, up
4.8% co mpared with the fourth quarter of fiscal 2025. Business unit revenue and growth rates compared with the prior year period were as follows:¹
Gross margin was 57.2% in the fourth quarter of fiscal 2026, c ompared with 58.4% in the fourth quarter of fiscal 2025.
The primary driver of the decrease in the gross margin percentage was a charge taken for pre-acquisition inventory and inventory purchase commitments transferred from the Attune Medical acquisition that was deemed not recoverable, partially offset by decreased restructuring costs related to portfolio rationalization initiatives and decreased amortization of fair value inventory step-up.
Operating expenses in the fourth quarter of fiscal 2026 were
$221.2 million, an increase of $99.5 million, or 81.8%, when compared with the prior year period, driven by the impairment of intangible assets related to Attune Medical, partially offset by remeasurements of contingent consideration. Due to these charges, the Company had operating losses of $23.0 million and a (6.6)% operating margin in the fourth quarter of fiscal 2026, compared with operating income of $71.3 million and an operating margin of 21.6% in the fourth quarter of fiscal 2025. The income tax rates were
29.1% and
18.0% in the fourth quarters of fiscal 2026 and fiscal 2025, respectively. Additionally, due to the charges above, fourth quarter fiscal 2026 net loss and loss per diluted share were $20.1 million and $(0.44), respectively, compared with net income and earnings per diluted share of $58.0 million and $1.17, respectively, in the fourth quarter of fiscal 2025.
ADJUSTED RESULTS
Fourth quarter fiscal 2026 organic revenue growth was
4.5% and organic ex-CSL revenue growth was
8.6% compared with the same period of fiscal 2025. Year-over-year organic and organic ex-CSL growth rates by business unit were as follows:
Fourth quarter fiscal 2026 adjusted gross margin was 59.7%, down⁵⁰ basis points compared with the prior year period. The primary drivers for the decrease in adjusted gross margin percentage were less favorable mix and impacts from tariffs, partially offset by higher volume and pricing benefits.
Adjusted operating expenses were $122.2 million, up $5.5 million, or 4.7%, when compared with the prior year period.
The increase in adjusted operating expenses was largely driven by the acquisition of Vivasure, impacts from tariff and performance-based compensation as well as additional growth investments. Adjusted operati ng income for the fourth quarter of fiscal 2026 was $84.5 million, up $2.2 million or 2.6%, and adjusted operating margin was 24.4%, down 50 basis points, compared with the same period of fiscal 2025. The adjusted income tax rates were 24.8% and
22.2% in the fourth quarters of fiscal 2026 and fiscal 2025, respectively.
Fourth quarter fiscal 2026 adjusted net income was $59.7 million, down $1.8 million, or 3.0%, and adjusted earnings per diluted share was $1.29, up 4.0%, each when compared with the same period of fiscal 2025.
Financial statements
Income Statement
Fourth Quarter Fiscal 2026 Reported — mpared with the fourth quarter of fiscal 2025. Business unit revenue and growth rates compared with the prior year period were as follows: (in millions)
| Fourth Quarter Fiscal 2026 Reported | Fourth Quarter Fiscal 2026 Reported | |
|---|---|---|
| Plasma | 130.3 | 2.8% |
| Blood Center | 56.4 | 0.7% |
| Hospital | 159.6 | 8.0% |
| Total net revenue | 346.4 | 4.8% |
Income Statement
Fourth Quarter Fiscal 2026 — compared with the same period of fiscal 2025. Year-over-year organic and organic ex-CSL growth rates by business unit were as follows:
| Fourth Quarter Fiscal 2026 – Organic | Fourth Quarter Fiscal 2026 – Organic ex-CSL | |
|---|---|---|
| Plasma | 1.8% | 12.7% |
| Blood Center | 5.5% | 5.5% |
| Hospital | 6.5% | 6.5% |
| Total net revenue | 4.5% | 8.6% |
Income Statement
| Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Three Months Ended – 3/28/2026 – (Data and Shares in Thousands, Except Per Share Data) | Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Three Months Ended – 3/28/2026 – (Data and Shares in Thousands, Except Per Share Data) | Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Three Months Ended – 3/29/2025 – (Data and Shares in Thousands, Except Per Share Data) | Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Three Months Ended – 3/29/2025 – (Data and Shares in Thousands, Except Per Share Data) | Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Three Months Ended – Inc/(Dec) % | Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Twelve Months Ended – 3/28/2026 – (Data and Shares in Thousands, Except Per Share Data) | Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Twelve Months Ended – 3/28/2026 – (Data and Shares in Thousands, Except Per Share Data) | Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Twelve Months Ended – 3/29/2025 – (Data and Shares in Thousands, Except Per Share Data) | Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Twelve Months Ended – 3/29/2025 – (Data and Shares in Thousands, Except Per Share Data) | Haemonetics Corporation Financial Summary – Condensed Consolidated Statements of (Loss) Income (Unaudited) – Twelve Months Ended – (Dec)/Inc % | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net revenues | 346,351 | 330,599 | 4.8% | 1,334,027 | 1,360,824 | -2.0% | |||||
| Cost of goods sold | 148,139 | 137,549 | 7.7% | 546,441 | 611,866 | -10.7% | |||||
| Gross profit | 198,212 | 193,050 | 2.7% | 787,586 | 748,958 | 5.2% | |||||
| Research and development | 14,446 | 15,914 | -9.2% | 59,766 | 62,722 | -4.7% | |||||
| Selling, general and administrative | 121,828 | 115,360 | 5.6% | 442,421 | 436,789 | 1.3% | |||||
| Amortization of acquired intangible assets | 10,491 | 11,296 | -7.1% | 43,998 | 48,261 | -8.8% | |||||
| Remeasurement of contingent consideration | -2,774 | -20,855 | -86.7% | -1,879 | -23,022 | -91.8% | |||||
| Impairment of intangible assets | 77,246 | 100.0% | 86,546 | 2,391 | 3519.7% | ||||||
| Total operating expenses | 221,237 | 121,715 | 81.8% | 630,852 | 527,141 | 19.7% | |||||
| Operating (loss) income | -23,025 | 71,335 | -132.3% | 156,734 | 221,817 | -29.3% | |||||
| Interest and other expense, net | -5,374 | -598 | 798.7% | -28,704 | -9,746 | 194.5% | |||||
| (Loss) income before (benefit) provision for income taxes | -28,399 | 70,737 | -140.1% | 128,030 | 212,071 | -39.6% | |||||
| (Benefit) provision for income taxes | -8,252 | 12,756 | -164.7% | 30,722 | 44,392 | -30.8% | |||||
| Net (loss) income | -20,147 | 57,981 | -134.7% | 97,308 | 167,679 | -42.0% | |||||
| Net (loss) income per share assuming dilution | -0.44 | 1.17 | -137.6% | 2.05 | 3.31 | -38.1% | |||||
| Weighted average number of shares: | Basic | 46,224 | 49,193 | 47,179 | 50,330 | ||||||
| Weighted average number of shares: | Diluted | 46,224 | 49,476 | 47,354 | 50,730 | ||||||
| Weighted average number of shares: | Profit Margins: | (Dec)/Inc % | Inc/(Dec) % | ||||||||
| Weighted average number of shares: | Gross profit | 57.2 | % | 58.4 | % | -1.2% | 59 | % | 55 | % | 4.0% |
| Weighted average number of shares: | Research and development | 4.2 | % | 4.8 | % | -0.6% | 4.5 | % | 4.6 | % | -0.1% |
| Weighted average number of shares: | Selling, general and administrative | 35.2 | % | 34.9 | % | 0.3% | 33.2 | % | 32.1 | % | 1.1% |
| Weighted average number of shares: | Operating (loss) income | -6.6 | % | 21.6 | % | -28.2% | 11.7 | % | 16.3 | % | -4.6% |
| Weighted average number of shares: | (Loss) income before (benefit) provision for income taxes | -8.2 | % | 21.4 | % | -29.6% | 9.6 | % | 15.6 | % | -6.0% |
| Weighted average number of shares: | Net (loss) income | -5.8 | % | 17.5 | % | -23.3% | 7.3 | % | 12.3 | % | -5.0% |
Income Statement
Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
| Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Gross profit | Gross profit | Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Gross profit | Gross profit | Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Operating expenses | Operating expenses | Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Operating expenses | Operating expenses | Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Operating (loss) income | Operating income (loss) | Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Operating (loss) income | Operating income (loss) | Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Interest and other (expense) income | Interest and other expense | Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Interest and other (expense) income | Interest and other expense | Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – (Benefit) provision for income taxes | Provision (benefit) for income taxes | Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – (Benefit) provision for income taxes | Provision (benefit) for income taxes | Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Net (loss) income | Net income (loss) | Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – Net (loss) income | Net income (loss) | Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – (Loss) earnings per diluted share(1)(2) | Earnings (loss) per diluted share | Reconciliation of Adjusted Measures for Fourth Quarter of FY26 and FY25 (Unaudited) – Three Months Ended March 28, 2026: – (Loss) earnings per diluted share(1)(2) | Earnings (loss) per diluted share | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported | 198,212 | 221,237 | -23,025 | -5,374 | -8,252 | -20,147 | -0.44 | |||||||||||||||||||||
| Amortization of acquired intangible assets | -10,491 | 10,491 | 2,471 | 8,020 | 0.17 | |||||||||||||||||||||||
| Acquisition, integration and transaction costs | 1,077 | -8,296 | 9,373 | 294 | 2,247 | 7,420 | 0.16 | |||||||||||||||||||||
| Restructuring costs | 77 | -119 | 196 | 48 | 148 | |||||||||||||||||||||||
| Restructuring related costs | -94 | -50 | -44 | -44 | ||||||||||||||||||||||||
| Digital transformation costs | -5,004 | 5,004 | 1,250 | 3,754 | 0.08 | |||||||||||||||||||||||
| Write down of certain assets | -172 | 172 | 86 | 86 | ||||||||||||||||||||||||
| Litigation-related charges | -443 | 443 | 107 | 336 | 0.01 | |||||||||||||||||||||||
| Impairment of intangible assets | -77,246 | 77,246 | 18,984 | 58,262 | 1.26 |
Cash Flow
Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
| Condensed Consolidated Statements of Cash Flows (Unaudited) – Twelve Months Ended – March 28, 2026 | Condensed Consolidated Statements of Cash Flows (Unaudited) – Twelve Months Ended – March 29, 2025 | ||
|---|---|---|---|
| Cash Flows from Operating Activities: | Net income | 97,308 | 167,679 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation and amortization | 111,717 | 115,586 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization of fair value inventory step-up | 5,814 | 14,956 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Share-based compensation expense | 33,827 | 29,636 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Impairment of intangible assets | 86,546 | 2,391 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Gain on repurchase of convertible senior notes, net | -12,600 | |
| Adjustments to reconcile net income to net cash provided by operating activities: | Gains on sales of property, plant and equipment | -714 | -15,698 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Deferred income taxes | -26,471 | -5,219 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Remeasurement of contingent consideration | -1,879 | -23,022 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Change in other non-cash operating activities | 10,726 | 9,978 |
| Change in operating assets and liabilities | Change in accounts receivable, net | -14,881 | 6,956 |
| Change in operating assets and liabilities | Change in inventories, net | 47,361 | -64,704 |
| Change in operating assets and liabilities | Change in prepaid income taxes | -4,534 | 226 |
| Change in operating assets and liabilities | Change in other assets and other liabilities | -35,028 | -25,232 |
| Change in operating assets and liabilities | Change in accounts payable and accrued expenses | -16,571 | -19,208 |
| Change in operating assets and liabilities | Net cash provided by operating activities | 293,221 | 181,725 |
| Cash Flows from Investing Activities: | Capital expenditures | -32,780 | -39,278 |
| Cash Flows from Investing Activities: | Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment | -51,891 | -21,112 |
| Cash Flows from Investing Activities: | Proceeds from divestiture and sale of assets | 43,291 | |
| Cash Flows from Investing Activities: | Proceeds from sale of property, plant and equipment | 1,375 | 23,253 |
| Cash Flows from Investing Activities: | Acquisitions | -60,180 | -150,906 |
| Cash Flows from Investing Activities: | Other investments | -36,071 | -17,143 |
| Cash Flows from Investing Activities: | Net cash used in investing activities | -179,547 | -161,895 |
| Cash Flows from Financing Activities: | Repayments, net of borrowings | -6,250 | 447,312 |
| Cash Flows from Financing Activities: | Purchase of capped call related to convertible notes | -88,200 | |
| Cash Flows from Financing Activities: | Debt issuance costs | -23,135 | |
| Cash Flows from Financing Activities: | Share repurchase | -175,000 | -225,000 |
| Cash Flows from Financing Activities: | Proceeds from employee stock programs | 7,893 | 8,333 |
| Cash Flows from Financing Activities: | Cash used to net share settle employee equity awards | -5,001 | -10,243 |
| Cash Flows from Financing Activities: | Other financing activities | -102 | -249 |
| Cash Flows from Financing Activities: | Net cash (used in) provided by financing activities | -178,460 | 108,818 |
| Cash Flows from Financing Activities: | Effect of exchange rates on cash and cash equivalents | 3,463 | -685 |
| Cash Flows from Financing Activities: | Net Change in Cash and Cash Equivalents | -61,323 | 127,963 |
| Cash Flows from Financing Activities: | Cash and Cash Equivalents at Beginning of the Period | 306,763 | 178,800 |
| Cash Flows from Financing Activities: | Cash and Cash Equivalents at End of Period | 245,440 | 306,763 |
| Free Cash Flow Reconciliation: | Cash provided by operating activities | 293,221 | 181,725 |
| Free Cash Flow Reconciliation: | Capital expenditures | -32,780 | -39,278 |
| Free Cash Flow Reconciliation: | Additions to Haemonetics equipment | -51,891 | -21,112 |
| Free Cash Flow Reconciliation: | Proceeds from sale of property, plant and equipment | 1,375 | 23,253 |
| Free Cash Flow Reconciliation: | Free cash flow | 209,925 | 144,588 |